Abstract:
A method for inhibiting the activity of 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) reductase in mammals comprises administering hesperidin or hesperetin thereto.
Abstract:
A .beta.-glucuronidase inhibitor comprising at least one compound selected from the group consisting of baicalin, oroxylin A-7-O-glucuronide and luteolin-3'-glucuronide; an extract of scutellaria root (baikal skullcap; Scutellariae Radix) and/or schizonepeta spike (Japanese catnip; Schizonepelae Spica); or a Chinese and Japanese traditional prescription comprised of scutellaria root (baikal skullcap; Scutellariae Radix) and/or schizonepeta spike (Japanese catnip; Schizonepelae Spica) as a crude drug. The .beta.-glucuronidase inhibitor can relieve the adverse effect, especially diarrhea, caused in the administration of a compound represented by the following formula I ##STR1##
Abstract:
The present invention relates, by way of novel industrial products which are useful in therapy, to the benzopyranone-.beta.-D-thioxyloside compounds of the formula ##STR1## in which: one of the substituents R or R' is an oxygen atom double-bonded to the corresponding cyclic carbon atom and the other is a group R.sub.1,the symbol represents a double bond conjugated to the CO group provided by one of the substituents R or R',X is a sulfur atom or an oxygen atom,R.sub.1 and R.sub.2, which are identical or different, are each a hydrogen atom, a C.sub.1 -C.sub.4 alkyl group, a halogen atom, a trifluoromethyl group or a phenyl group, it being possible for R.sub.1 and R.sub.2, taken together, to form a 7,8,9,10-tetrahydrodibenzo[b,d]pyran-6-one group or a 1,2,3,4-tetrahydro-9H-xanthen-9-one group with the benzopyranone group to which they are bonded, andY is the hydrogen atom or an aliphatic acyl group.
Abstract:
Acetals and ketals of benzopyran glycosides, prepared by condensing a benzopyran glycoside with a carbonyl compound using a chloroformate ester as condensing agent, show enhanced activity in treating capillary fragility and related pathologies, as well as effectiveness in modifying the evolution of diabetic cataracts.
Abstract:
A process for manufacturing pure diosmin suitable as a therapeutic agent comprising acetylating hesperidin, observing by means of ultraviolet absorption the progress of the acetylation reaction and continuing such reaction until there disappears the band initially occurring at a wave length in the range of 264 to 280 nm and there appears in place thereof a new maximum at a wave length of about 330 nm. Thereafter the acetylation product is brominated, the obtained bromination product hydrolyzed and the obtained product after precipitation isolated, in order to obtain diosmin having a bromine content less than 0.1%.
Abstract:
New compounds which are monobasic metal salts of dihydrochalcones and the method of their preparation, the monosodium, monopotassium, and monocalcium salts being useful as sugar substitutes and sweetening agents for foods and beverages.
Abstract:
Modified flavonoid glycosides are prepared wherein the molecules include two or more glucose substituents. Such modified flavonoid glycosides exhibit uniquely higher solubilities than the unmodified compounds. Modification is achieved by reacting flavonoid monoglycosides with starchy materials in the presence of Alpha -amylase enzymes. The resultant flavonoid glycosides include principally two or three glucose substituents per molecule. Further reaction of the modified glycosides with Beta -amylase gives rise to decomposition of the glycoside having a high polymerization degree and a flavonoid glycoside having two or three glucoses per molecule is solely obtained.